



# Immunaqua - Antimicrobial immune effectors in marine invertebrates: characterization and application for disease control in aquaculture



### Co-ordinating Institution



Dr. Evelyne Bachère  
Ifremer/CNRS/LIM2, UMR 5171  
2 Place E. Bataillon, CC 80  
34095- Montpellier, France  
ebachere@ifremer.fr



Dr. Philippe Bulet  
Atheris Laboratory  
CH-1228, Plan Les Ouates,  
Geneve, Witzerland  
philippe.bulet@atheris.ch



Prof. Patrick Sorgeloos  
Ghent University,  
Rozie 44  
9000- Ghent, Belgium  
Patrick.Sorgeloos@ruug.ac.be



Dr. Jean-Louis Nicolas  
Ifremer, DRV/RA, LPI  
Centre de Brest, BP 70  
29280-Plouzané, France  
jlnicolas@ifremer.fr



Prof. Marjherita Barracco  
University Santa Catarina  
CP 476, 88.040-900-  
Florianopolis, Brazil  
Barracco@mbbox1.ufsc.br



Dr. Sergio Marshall  
Inst. Biología, Lab. Genética,  
Avenida Brasil 2950, PB 4059  
Valparaíso, Chile  
smarshall@ucv.cl



Dr. Anchalee Tassanakorn  
Chulalongkorn University  
Phayathai Road  
10330-Bangkok, Thailand  
Anachalee.k@chula.ac.th



Prof. Jianhui Xiang  
Inst. Oceanol. Chinese Acad of Sc.  
Nanhai Road N°7,  
266071-Qingdao, China  
jhxjiang@ms.gdio.ac.cn



As world aquaculture is facing economical losses due to infectious diseases, collaborative work is currently developed in the frame of the EC INCO-DEV program, Immunaqua (ICA4-CT-2001-10023) <http://www.ifremer.fr/immunaqua>

- Isolate and characterize antimicrobial molecules, effectors of innate immunity.
  - Investigate their *in vitro* activities against wide range of microorganisms and pathogens.
  - Monitor their effect on larvae and live food for their potential beneficial and/or protective effect against infections.
- ➔ To develop methodologies alternative to the use of antibiotics and chemicals for larvae treatments.

**Objectives**

The objectives are to provide new antimicrobial agents and new approaches for the control of infectious diseases in mollusc and shrimp aquaculture.

- develop quantitative methods for analyses of immune effectors gene expression at population level applicable for health monitoring and/or selection
- ➔ To develop Marker-Assisted Selection programmes using immune genes as potential markers for increased non-specific response to diseases or for health improvement.

